We therefore propose that future experimental work is needed (e.g., treatment of ovarian cancer cell lines and endothelial co-cultures under hypoxia) to test whether CAPE indeed suppresses HIF-1α stabilisation and VEGF-A production in ovarian cancer. This evidence concerns the gene HIF1A and ovarian carcinoma.